Macroglobulinemia
Watchlist
Retrieved
2021-01-18
Source
Trials
—
Genes
MYD88,
IL6,
BTK,
PAX5,
CXCR4,
BCL2,
IGH,
KRT20,
CD19,
MS4A1,
MIR155,
TP53,
CXCL12,
IRAK1,
STOML2,
IL4,
IRF4,
UCHL5,
CD40LG,
CD27,
HAS1,
MYOM2,
USP14,
SDC1,
CDR3,
SYK,
TP73,
ZAP70,
IL10,
ANPEP
MYD88,
IL6,
BTK,
PAX5,
CXCR4,
BCL2,
IGH,
KRT20,
CD19,
MS4A1,
MIR155,
TP53,
CXCL12,
IRAK1,
STOML2,
IL4,
IRF4,
UCHL5,
CD40LG,
CD27,
HAS1,
MYOM2,
USP14,
SDC1,
CDR3,
SYK,
TP73,
ZAP70,
IL10,
ANPEP,
MALT1,
NAMPT,
TNFSF13B,
LPL,
TNFSF13,
MYC,
PIK3CD,
SMUG1,
AKT1,
BACH2,
MTOR,
AICDA,
FCGR3A,
FCER2,
BCR,
TCL1A,
RAPH1,
ARHGAP24,
SLC28A1,
EGLN3,
TNFSF10,
TNFRSF13C,
TNFSF11,
ARID1A,
PRIMA1,
IGHV3OR16-7,
AIMP2,
GRAP2,
SLC35B2,
LAPTM5,
MIR206,
MIR23B,
XPO1,
XBP1,
VWF,
VEGFA,
MIR363,
LOC102723407,
CLEC12A,
HDAC9,
TCL1B,
ANP32B,
POLDIP2,
IBTK,
RNF19A,
IGHV4-34,
MAPK8IP2,
TNFAIP3,
ACSBG1,
IGHV3-69-1,
IGHV3-23,
CD274,
BLNK,
ZHX2,
ADAMTS13,
IRAK4,
LEF1,
TLR7,
AHSA1,
COLEC10,
CXCL13,
EGLN1,
EXOC2,
TNFRSF13B,
PXN,
TNF,
CD70,
HCK,
HAS2,
GLI2,
FGFR3,
EFNB2,
CTRL,
CTNNB1,
MAPK14,
CRP,
CRK,
CD52,
CDKN2A,
CD79B,
CD79A,
CD40,
HMMR,
CD38,
TNFRSF8,
CD22,
CD6,
CCND3,
CBL,
SERPING1,
BSG,
BRAF,
BLM,
BCL9,
BCL6,
CCND1,
ANXA5,
HCLS1,
IL1B,
AURKA,
PLCG2,
STAT5B,
STAT5A,
SPIB,
SPI1,
SOAT1,
CCL3,
RAF1,
PTPRC,
MAPK3,
MAPK1,
PRKCD,
POU2F2,
POU2F1,
POU2AF1,
PIK3CG,
IL2RA,
PIK3CB,
PIK3CA,
NOTCH2,
NOS2,
NOS1,
NCAM1,
CD200,
MMP8,
MCL1,
KIT,
ITGAM,
ITGA4,
ISG20,
IL4R,
LOC102724971
Drugs
18-(p-(,
Acalabrutinib
(
CALQUENCE
),
Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus
18-(p-(,
Acalabrutinib
(
CALQUENCE
),
Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus,
Bendamustine for 50 ml admixture
(
BENDEKA
),
Cladribine
(
LITAK
),
Everolimus
(
AFINITOR,
VOTUBIA
),
Ibrutinib
(
IMBRUVICA
),
Idelalisib
(
ZYDELIG
),
Iodine (131I) tositumomab,
Oprozomib,
haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate
Registered!
Macroglobulinemia is the presence of increased levels of macroglobulins in the circulating blood. It is a plasma cell dyscrasia, resembling leukemia, with cells of lymphocytic, plasmacytic, or intermediate morphology, which secrete a monoclonal immunoglobulin M component. There is diffuse infiltration by the malignant cells of the bone marrow and also, in many cases, of the spleen, liver, or lymph nodes. The circulating macroglobulin can produce symptoms of hyperviscosity syndrome: weakness, fatigue, bleeding disorders, and visual disturbances. Peak incidence of macroglobulinemia is in the sixth and seventh decades of life. (Dorland, 28th ed)
See also
- Waldenström macroglobulinemia
- Hematopoietic ulcer